China Pharma (NYSE:CPHI) Shares Gap Down – Here’s Why

China Pharma Holdings, Inc. (NYSE:CPHI)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $0.91, but opened at $0.86. China Pharma shares last traded at $13.3290, with a volume of 51,706,259 shares traded.

China Pharma Trading Down 78.9%

The firm has a market capitalization of $69.29 million, a PE ratio of -3.11 and a beta of 1.14. The company’s fifty day simple moving average is $0.94 and its 200-day simple moving average is $0.83. The company has a debt-to-equity ratio of 0.22, a current ratio of 0.79 and a quick ratio of 0.26.

Institutional Investors Weigh In On China Pharma

A hedge fund recently raised its position in China Pharma stock. Citadel Advisors LLC lifted its holdings in shares of China Pharma Holdings, Inc. (NYSE:CPHI) by 31.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 30,426 shares of the company’s stock after purchasing an additional 7,356 shares during the quarter. Citadel Advisors LLC owned about 0.93% of China Pharma worth $59,000 as of its most recent filing with the Securities and Exchange Commission.

China Pharma Company Profile

China Pharma Holdings, Inc develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People’s Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension.